Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 920 active trials
348 drugs · 19,214 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 2 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Erlotinib | Approved | Phase 4 | 12 | 6 | 51 | 389 | 23 | CA, EU, US | Sep 19, 2005 | 2001-05 |
| Thalidomide | Approved | Phase 4 | 12 | 4 | 47 | 235 | 5 | EU, US | Jul 16, 1998 | 1995-09 |
| Duvelisib | Approved | Phase 3 | 12 | 6 | 5 | 40 | 3 | EU, US | Sep 24, 2018 | 2013-05 |
| Quizartinib | Approved | Phase 3 | 12 | 8 | 5 | 33 | 4 | CA, EU, US | Jul 20, 2023 | 2007-01 |
| Futibatinib | Approved | Phase 3 | 12 | 8 | 5 | 20 | 2 | EU, US | Sep 30, 2022 | Jul 21, 2014 |
| Olutasidenib | Approved | Phase 4 | 12 | 10 | 0 | 14 | 1 | US | Dec 1, 2022 | Nov 1, 2018 |
| Odronextamab | Approved | Phase 3 | 12 | 9 | 6 | 13 | 1 | EU | Aug 22, 2024 | Jan 11, 2016 |
| Asparaginase | Approved | Phase 4 | 11 | 4 | 43 | 111 | 3 | CA, EU | Jan 14, 2016 | 1990-01 |
| Megestrol | Approved | Phase 4 | 11 | 6 | 15 | 43 | 14 | CA, US | Aug 8, 1988 | 1987-12 |
| Tagraxofusp | Approved | Phase 2 | 11 | 8 | 0 | 19 | 3 | EU, US | Dec 21, 2018 | 2013-05 |
| Tebentafusp | Approved | Phase 3 | 11 | 10 | 2 | 17 | 3 | CA, EU, US | Jan 25, 2022 | 2010-09 |
| Trastuzumab Deruxtecan | Approved | Phase 3 | 11 | 5 | 2 | 12 | 21 | US | Dec 20, 2019 | Nov 12, 2020 |
| Temsirolimus | Approved | Phase 4 | 10 | 3 | 7 | 171 | 7 | CA, EU, US | May 30, 2007 | 2000-09 |
| Denosumab | Approved | Phase 4 | 10 | 2 | 27 | 71 | 63 | EU, US | May 26, 2010 | Aug 1, 2004 |
| Dinutuximab | Approved | Phase 3 | 10 | 3 | 4 | 19 | 3 | CA, EU, US | Mar 10, 2015 | Oct 26, 2001 |
| Ropeginterferon Alfa-2b | Approved | Phase 4 | 10 | 4 | 6 | 16 | 4 | CA, US | Nov 12, 2021 | Aug 30, 2013 |
| Gefitinib | Approved | Phase 4 | 9 | 1 | 49 | 259 | 10 | CA, EU, US | Dec 17, 2003 | 1999-09 |
| Zoledronic Acid | Approved | Phase 4 | 9 | 4 | 68 | 172 | 14 | EU, US | Mar 20, 2001 | 1998-08 |
| Clofarabine | Approved | Phase 3 | 9 | 7 | 8 | 131 | 4 | CA, EU, US | May 29, 2006 | 1999-02 |
| Plerixafor | Approved | Phase 4 | 9 | 5 | 4 | 75 | 7 | CA, EU, US | Dec 15, 2008 | 2004-05 |
| Trabectedin | Approved | Phase 3 | 9 | 9 | 15 | 68 | 7 | CA, EU, US | Sep 17, 2007 | 1996-02 |
| Rucaparib | Approved | Phase 3 | 9 | 2 | 8 | 59 | 10 | EU, US | Dec 19, 2016 | 2007-12 |
| Tisagenlecleucel | Approved | Phase 3 | 9 | 4 | 5 | 41 | 2 | CA, EU | Aug 23, 2018 | Mar 17, 2010 |
| Pralatrexate | Approved | Phase 4 | 9 | 6 | 6 | 38 | 3 | CA, US | Sep 24, 2009 | 1999-07 |
| Tepotinib | Approved | Phase 3 | 9 | 6 | 1 | 22 | 4 | CA, EU, US | Feb 3, 2021 | Nov 30, 2009 |
| Mirdametinib | Approved | Phase 2 | 9 | 8 | 0 | 20 | 1 | EU | Jul 17, 2025 | 2004-02 |
| Avapritinib | Approved | Phase 4 | 9 | 7 | 1 | 18 | 9 | CA, EU, US | Jan 9, 2020 | 2015-08 |
| Lisocabtagene Maraleucel | Approved | Phase 3 | 9 | 4 | 1 | 18 | 2 | CA, EU | Apr 4, 2022 | Nov 27, 2017 |
| Imlunestrant | Approved | Phase 3 | 9 | 4 | 2 | 10 | 2 | EU, US | Sep 25, 2025 | Dec 10, 2019 |
| Erlotinib Hydrochloride | Approved | Phase 3 | 8 | 1 | 14 | 183 | 4 | US | Nov 5, 2019 | Jul 23, 2001 |
| Hydroxyurea | Approved | Phase 4 | 8 | 7 | 19 | 64 | 13 | CA, US | Dec 7, 1967 | 1994-10 |
| Belinostat | Approved | Phase 3 | 8 | 4 | 2 | 49 | 1 | US | Jul 3, 2014 | 2005-01 |
| Talimogene Laherparepvec | Approved | Phase 3 | 8 | 2 | 4 | 41 | 1 | EU | Dec 16, 2015 | 2005-12 |
| Tegafur | Approved | Phase 4 | 8 | 5 | 8 | 38 | 1 | EU | Mar 14, 2011 | 1996-04 |
| Mogamulizumab | Approved | Phase 4 | 8 | 7 | 1 | 31 | 3 | CA, EU, US | Aug 8, 2018 | 2007-02 |
| Vorasidenib | Approved | Phase 3 | 8 | 2 | 4 | 12 | 4 | CA, EU, US | Aug 6, 2024 | 2015-06 |
| Imiquimod | Approved | Phase 4 | 7 | 3 | 28 | 108 | 4 | EU, US | Sep 18, 1998 | 1999-06 |
| Valproic Acid | Approved | Phase 4 | 7 | 6 | 0 | 57 | 1 | US | Jul 1, 1986 | 2003-07 |
| Idelalisib | Approved | Phase 4 | 7 | 4 | 14 | 53 | 4 | CA, EU, US | Jul 23, 2014 | 2008-06 |
| Capmatinib | Approved | Phase 4 | 7 | 4 | 5 | 47 | 5 | CA, EU, US | May 6, 2020 | 2010-01 |
| Brigatinib | Approved | Phase 3 | 7 | 3 | 2 | 27 | 9 | CA, EU, US | Apr 28, 2017 | Sep 20, 2011 |
| Pralsetinib | Approved | Phase 4 | 7 | 4 | 2 | 13 | 5 | CA, EU, US | Sep 4, 2020 | Mar 17, 2017 |
| Tovorafenib | Approved | Phase 3 | 7 | 4 | 1 | 13 | 7 | CA, EU, US | Apr 23, 2024 | Sep 15, 2011 |
| Zongertinib | Approved | Phase 3 | 7 | 4 | 2 | 7 | 2 | US | Aug 8, 2025 | Jul 2, 2021 |
| Imatinib Mesylate | Approved | Phase 4 | 6 | 2 | 21 | 188 | 26 | US | Apr 18, 2003 | May 7, 1993 |
| Procarbazine | Approved | Phase 3 | 6 | 2 | 21 | 57 | 2 | CA, US | Jul 22, 1969 | 1989-02 |
| Chlorambucil | Approved | Phase 4 | 6 | 1 | 30 | 46 | 2 | CA, US | Mar 18, 1957 | 1993-11 |
| Ceritinib | Approved | Phase 4 | 6 | 2 | 3 | 39 | 3 | CA, EU, US | Apr 29, 2015 | Jan 24, 2011 |
| Midostaurin | Approved | Phase 3 | 6 | 2 | 7 | 39 | 7 | CA, EU, US | Apr 28, 2017 | Jan 30, 2002 |
| Bosutinib | Approved | Phase 4 | 6 | 3 | 5 | 35 | 15 | CA, EU, US | Sep 4, 2012 | 2004-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.